AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
sulfadimidine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| anti-infectives, sulfonamides | 2502 | 57-68-1 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A sulfanilamide anti-infective agent. It has a spectrum of antimicrobial action similar to other sulfonamides.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 4 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 153.98 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 86.50 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | -0.192 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 3.565 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 19.454 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 0.953 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 59.770 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 73.680 | % | High | 1 |
| herg | hERG pIC50 | 3.865 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 1.045 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 3.105 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 52.300 | % | High | 1 |
| kinase-safety-class | ACVR2A,ACVR2B,ALK,AURKA,AURKB,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK1,CDK5,CDK9,CHEK1,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GRK3,GSK3B,ITK,JAK1,JAK2,KIT,MAP3K1,MAP3K21,MAP3K7,MAP4K1,MAPK12,MAPK7,MAPK9,MARK4,MTOR,NTRK2,PAK4,PDK2,PDK4,PDPK1,PIK3CB,PIK3CD,PIM2,PRKCD,PRKDC,SGK1,SIK2,SIK3,STK33,SYK,TEK,TTK,ULK1 | 54 | |||
| kinase-selectivity-class | ACVR2A,AURKA,AXL,BRAF,CDK9,DDR1,DYRK1B,EPHB4,ERBB2,FGFR1,GRK2,JAK1,MAP2K6,MAP4K1,MAPK7,MARK4,SIK2,SIK3,STK33,SYK,TEK,ULK1 | 22 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 9.057 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 3.162 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 61.970 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 6.668 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 68.530 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 0.984 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 93.750 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 31.270 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 676.083 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Aug. 16, 1949 | FDA | LEDERLE |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | J01EB03 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE SULFONAMIDES AND TRIMETHOPRIM Short-acting sulfonamides |
| ATC | J01EE05 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE SULFONAMIDES AND TRIMETHOPRIM Combinations of sulfonamides and trimethoprim, incl. derivatives |
| MeSH PA | D000890 | Anti-Infective Agents |
| CHEBI has role | CHEBI:33281 | antimicrobial agent |
| CHEBI has role | CHEBI:33282 | antibacterial agent |
| CHEBI has role | CHEBI:35441 | antiinfective agent |
| CHEBI has role | CHEBI:35703 | xenobiotic |
| CHEBI has role | CHEBI:36047 | antibacterial drug |
| CHEBI has role | CHEBI:50502 | EC 2.5.1.15 (dihydropteroate synthase) inhibitor |
| CHEBI has role | CHEBI:50903 | carcinogenic agent |
| CHEBI has role | CHEBI:52214 | ligand |
| CHEBI has role | CHEBI:78298 | environmental contaminant |
| CHEBI has role | CHEBI:88188 | drug allergen |
Related Drugs by ATC class:
J01EB Short-acting sulfonamides 7 drugs
J01EE Combinations of sulfonamides and trimethoprim, incl. derivatives 7 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Third trimester pregnancy | contraindication | 41587001 | |
| Megaloblastic anemia due to folate deficiency | contraindication | 85649008 | DOID:14026 |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Anemia due to enzyme deficiency | contraindication | 111577008 | |
| Disease of blood AND/OR blood-forming organ | contraindication | 191124002 | DOID:74 |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Breastfeeding (mother) | contraindication | 413712001 | |
| Porphyria | contraindication | 418470004 |
🐶 Veterinary Drug Use
| Species | Use | Relation |
|---|---|---|
| Cattle | Bacterial pneumonia | Indication |
| Cattle | Respiratory disease complex caused by Pasteurella species | Indication |
| Cattle | Colibacillosis caused by Escherichia coli | Indication |
| Cattle | Necrotic pododermatitis (foot rot) caused by Fusobacterium necrophorum | Indication |
| Cattle | Diphtheria caused by Fusobacterium necrophorum | Indication |
| Cattle | Acute metritis caused by Streptococcus species | Indication |
| Cattle | Acute mastitis caused by Streptococcus species | Indication |
| Chickens | Infectious coryza caused by Avibacterium paragallinarium | Indication |
| Chickens | Coccidiosis cased by Eimeria tenella | Indication |
| Chickens | Pullorum disease caused by Salmonella Pullorum | Indication |
| Chickens | Coccidiosis cased by Eimeria necatrix | Indication |
| Chickens | Cholera caused by Pasteurella multocida | Indication |
| Swine | Colibacillosis caused by Escherichia coli | Indication |
| Swine | Bacterial pneumonia caused by Pasteurella multocida | Indication |
| Turkeys | Coccidiosis caused by Eimeria adenoeides | Indication |
| Turkeys | Coccidiosis caused by Eimeria adenoeides | Indication |
| Cattle | Bacterial pneumonia | Indication |
| Cattle | Bovine respiratory disease complex caused by Pasteurella species | Indication |
| Cattle | Colibacillosis caused by Escherichia coli | Indication |
| Cattle | Necrotic pododermatitis (foot rot) caused by Fusobacterium necrophorum | Indication |
| Cattle | Diphtheria caused by Fusobacterium necrophorum | Indication |
| Cattle | Acute metritis caused by Streptococcus species | Indication |
| Cattle | Acute mastitis caused by Streptococcus species | Indication |
| Chickens | Coryza caused by Avibacterium paragallinarum | Indication |
| Chickens | Coccidiosis caused by Eimeria tenella | Indication |
| Chickens | Coccidiosis caused by Eimeria necatrix | Indication |
| Chickens | Cholera caused by Pasteurella multocida | Indication |
| Chickens | Pullorum disease caused by Salmonella Pullorum | Indication |
| Swine | Colibacillosis caused by Escherichia coli | Indication |
| Swine | Bacterial pneumonia caused by Pasteurella species | Indication |
| Turkeys | Coccidiosis caused by Eimeria meleagrimitis | Indication |
| Turkeys | Coccidiosis caused by Eimeria adenoeides | Indication |
🐶 Veterinary products
| Product | Applicant | Ingredients |
|---|---|---|
| Sulmet Drinking Water Solution, 12.5% | Huvepharma EOOD | 1 |
| Sulmet Solution Injectable | Huvepharma EOOD | 1 |
| Aureomix S 40/40 Granular | Zoetis Inc. | 2 |
| Aureo S 700 Granular, Aureo S 700 | Zoetis Inc. | 2 |
| Tylan 5 Sulfa-G, Tylan 10 Sulfa-G, Tylan 20 Sulfa-G, Tylan 40 Sulfa-G | Elanco US Inc. | 2 |
| AUREOMIX S 700-A | Zoetis Inc. | 2 |
| AUREOMIX S 700-D | Zoetis Inc. | 2 |
| Aureomix S 700-G | Zoetis Inc. | 2 |
| Aureomix S 700-E | Zoetis Inc. | 2 |
| Aureomix 700-F | Zoetis Inc. | 2 |
| Aureomix S 700-C | Zoetis Inc. | 2 |
| AUREOMIX S 700-B | Zoetis Inc. | 2 |
| AUREOMIX S 700-H | Zoetis Inc. | 2 |
| Sulfamethazine Spanbolet II | Zoetis Inc. | 1 |
| Chloronex Sulmet | Huvepharma EOOD | 2 |
| Tylan 10 Sulfa-G, Tylan 40 Sulfa-G | Zoetis Inc. | 2 |
| PoultrySulfa | Huvepharma EOOD | 3 |
| Sustain III Bolus, Sustain III Calf Bolus | Bimeda Animal Health Limited | 1 |
| Sulmet Oblets | Huvepharma EOOD | 1 |
| Sulmet Soluble Powder | Huvepharma EOOD | 1 |
| Calfspan | Zoetis Inc. | 1 |
| Pennchlor S 40/40 | Pharmgate Inc. | 2 |
| Sulfamethazine Sustained Release Bolus | Huvepharma EOOD | 1 |
| Veta-Meth | Lloyd Inc. | 1 |
| Sulka-S Bolus | Zoetis Inc. | 1 |
| Aureo S 700 and Bovatec | Zoetis Inc. | 3 |
| Pennchlor S | Pharmgate Inc. | 2 |
| SMZ-Med 454 | Bimeda Animal Health Limited | 1 |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 7.24 | acidic |
| pKa2 | 2.88 | Basic |
| pKa3 | 2.27 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Lactoylglutathione lyase | Enzyme | WOMBAT-PK | |||||||
| Dihydropteroate synthase | Enzyme | INHIBITOR | CHEMBL | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4017499 | VUID |
| N0000145884 | NUI |
| D02436 | KEGG_DRUG |
| 4017499 | VANDF |
| C0038686 | UMLSCUI |
| CHEBI:102265 | CHEBI |
| CHEMBL446 | ChEMBL_ID |
| DB01582 | DRUGBANK_ID |
| 5327 | PUBCHEM_CID |
| 12642 | IUPHAR_LIGAND_ID |
| 1981-58-4 | SECONDARY_CAS_RN |
| 10178 | RXNORM |
| NOCODE | MMSL |
| 002817 | NDDF |
| 324417001 | SNOMEDCT_US |
| 40036000 | SNOMEDCT_US |
| D013418 | MESH_DESCRIPTOR_UI |
| 24540-76-9 | SECONDARY_CAS_RN |
| 1068 | INN_ID |
| 48U51W007F | UNII |
Pharmaceutical products:
None